2Fibulin-5 Inhibits Proliferation of Endometrial Carcinoma Ishikawa Cells by Down-Regulating β-Catenin

Endometrial cancer is a malignance in the uterus. The incidence of endometrial cancer is increasing recent years. Fibulin-5 participates in tissue homeostasis. The exact role of Fibulin-5 in endometrial cancer, such as becoming a sensitive tumor marker for endometrial cancer for diagnosis and follow-up, remains to be determined. 30 cases of endometrial tissue cancer specimens and adjacent tissues were collected for analysis of the expression of Fibulin-5 by western blot. Endometrial carcinoma Ishikawa cells (ECICs) were cultured and the level of Fibulin-5 was regulated via transfection. β-catenin level was measured followed by analysis of cell viability by MTT assay or BrdU staining. Results showed that Fibulin-5 in endometrial carcinoma tissues was significantly downregulated compared to para cancer tissues. Overexpression of Fibulin-5 decreased cell viability of endometrial carcinoma Ishikawa cells (ECICs) whereas downregulation increased cell viability. Meanwhile, Fibulin-5 overexpression significantly downregulated β-catenin and β-catenin knockdown blocked the proliferation effect caused by Fibulin-5 on ECICs. In conclusion, Fibulin-5 could inhibit cancer cell proliferation possibly via β-catenin related pathway.

Download Full-text

Long Non-Coding RNA Small Nucleolar RNA Host Gene 1 and MicroRNA-100-3p Expression in Endometrial Carcinoma and Its Effect on the Proliferation and Apoptosis of Ishikawa Cells

Journal of Biomaterials and Tissue Engineering ◽

10.1166/jbt.2021.2505 ◽

2021 ◽

Vol 11 (6) ◽

pp. 1046-1052

Author(s):

Jiana Mao ◽

Yulan Liu ◽

Cainuo Shen ◽

Xiaoxia Duan ◽

Yier Chen

Keyword(s):

Endometrial Cancer ◽

Cell Viability ◽

Caspase 3 ◽

Pcr Assay ◽

Cell Ratio ◽

Apoptosis Rate ◽

Qrt Pcr ◽

Proliferation And Apoptosis ◽

Ishikawa Cells ◽

Cancer Tissues

The aim of this study was to explore LncRNA SNHG1 and miRNA-100-3p expression in endometrial carcinoma and its effect on the proliferation and apoptosis of Ishikawa cells. A qRT-PCR assay was conducted to determine SNHG1 and miRNA-100-3p expression in endometrial cancer tissues and paracancerous tissues. Human endometrial cancer Ishikawa cells were cultured in vitro. Si-NC, si-SNHG1, si-SNHG1, anti-miRNA-NC, and si-SNHG1 were transfected into Ishikawa cells with anti-miRNA-519b-3p. A qRT-PCR assay was performed to determine SNHG1 and miRNA-100-3p expression, and the CCK-8 method was used to determine cell proliferation. Flow cytometry was conducted to determine cell cycle and apoptosis rate and a dualluciferase reporter experiment was carried out to test the targeting association between SNHG1 and miRNA-100-3p. Cleave Caspase-3, CHOP, and ATF4 expression were determined with the Western Blot method. SNHG1 expression level and miRNA-519b-3p expression level were much higher and much lower, respectively, in endometrial cancer tissues than in paracancerous tissues (P < 0.05). Transfection of si-SNHG1 can greatly attenuate cell viability and S cell ratio (P < 0.05), and increase G0/G1 cell ratio, apoptosis rate, Cleaved Caspase-3, CHOP, and ATF4 protein level (P < 0.05) compared to the si-NC group. Furthermore, the double luciferase reporter experiment confirmed that SNHG1 can competitively combine withmiRNA-100-3p. Also, co-transfection of si-SNHG1 and anti-miRNA-100-3p could significantly increase cell viability and S cell ratio (P < 0.05), and decrease G0/G1 cell ratio and apoptosis rate, and Cleaved Caspase-3, CHOP, and ATF4 protein levels compared to si-SNHG1+anti-miRNA-NC (P < 0.05). Interfering with SNHG1 could inhibit the proliferation of Ishikawa cells and promote apoptosis by upregulating miRNA-100-3p expression.

Download Full-text

Bu Shen Yang Xue Prescription Has Treating Effect on Endometrial Cancer through FSH/PI3K/AKT/Gankyrin/HIF-α/cyclinD 1 Pathway in Ishikawa Cells

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2018/8412984 ◽

2018 ◽

Vol 2018 ◽

pp. 1-10

Author(s):

Yue-qun Chen ◽

Hua-li Fei ◽

Hong-li Zhu

Keyword(s):

Endometrial Cancer ◽

Endometrial Carcinoma ◽

Cancer Cell ◽

Nude Mice ◽

Follicle Stimulating Hormone ◽

Control Group ◽

Model Group ◽

Migration Ability ◽

Ishikawa Cells ◽

And Migration

Background. The formulation of Bu Shen Yang Xue (BSYX) has been clinically used in treating gynecologic disease in China, especially for the development of the endometrium. Endometrial carcinoma is the most common malignant tumor of the female genital tract in developed countries. And few studies have been reported on the antitumor activity of BSYX. Therefore, this study aimed to investigate the effect of BSYX on endometrial cancer and make an initial discussion of the underlining mechanisms in Ishikawa cells. Methods and Results. Firstly, 60 SPF female nude mice were randomly divided into control group, model group, BSYX group, and positive group. The models of subcutaneous tumor xenograft of nude mice were established by injection of human endometrial carcinoma cell line Ishikawa tumor cell suspension. Compared with model group, BSYX reduced effectively tumor volume and changed pathological feature in mice tumor issue. Meanwhile, proteins from tumor issues were detected by western blot analysis. The protein levels of follicle-stimulating hormone receptor (FSHR), p-Akt/Akt, Gankyrin, and cyclinD1 in the model group were higher than those in control group but the expression in BSYX group was lower than that in the model group. The hypoxia inducible factor alpha (HIF-α) protein level in the model group was lower than those in control group and upregulated in BSYX group. In addition, Ishikawa cells were cultured and then exposed to follicle-stimulating hormone (FSH), LY294002, a highly selective PI3K inhibitor and serum containing BSYX, respectively. LY294002 and BSYX markedly decreased the cancer cell viability and migration ability and increased the apoptosis rate. FSH promoted the cancer cell ability and migration ability. LY294002 and BSYX evidently downregulated the proteins levels of FSHR, p-Akt/Akt, Gankyrin, and cyclinD1 and upregulated the expression of HIF-α protein, and FSH was on the opposite. Conclusions. Taken together, our results showed that the formulation of BSYX had antitumor effect on endometrial cancer in vivo and in vitro and was related with FSH/PI3K/AKT/Gankyrin/HIF-α/cyclinD1 transduction pathway.

Download Full-text

Is there a role for CA-125 in monitoring patients with early endometrial cancer?

International Journal of Gynecological Cancer ◽

10.1046/j.1525-1438.1991.01040169.x ◽

1991 ◽

Vol 1 (4) ◽

pp. 169-172

Author(s):

M. Prefontaine ◽

G. J. O'Connell ◽

E. Ryan ◽

K. J. Murphy

Keyword(s):

Endometrial Cancer ◽

Positive Predictive Value ◽

Endometrial Carcinoma ◽

Predictive Value ◽

Clinical Status ◽

Statistical Correlation ◽

Ca 125 ◽

Recurrent Malignancy ◽

Low Prevalence

Elevated CA-125 levels have been reported in some women with endometrial carcinoma. Current follow-up policy for these patients does not involve the use of tumor markers. CA-125 measurements were performed in 28 patients with a diagnosis of endometrial cancer, 14 clinically free of disease and 14 with known disease. Based on the sensitivity (0.64) and specificity (0.93) observed we constructed a model to estimate the predictive value of the assay as a marker in the follow-up of patients who have completed treatment. This model would involve a CA-125 assay every six months for five years in 100 patients with stage I and II disease. Despite the high statistical correlation between the clinical status of the patient and the CA-125 value observed in our study, the positive predictive value would be approximately 24% in such a follow-up protocol where a low prevalence of recurrent malignancy is expected.

Download Full-text

Bafetinib inhibits ishikawa cells growth through modulating p16 expression

International Journal of Basic and Applied Sciences ◽

10.14419/ijbas.v6i3.7860 ◽

2017 ◽

Vol 6 (3) ◽

pp. 42

Author(s):

Mohammad Althubiti

Keyword(s):

Endometrial Cancer ◽

Kinase Inhibitors ◽

Kinase Inhibitor ◽

Ishikawa Cell ◽

Proliferative Effect ◽

Cycle Arrest ◽

Ishikawa Cells ◽

And Control ◽

P16 Expression

Bafetinib is a tyrosine kinase inhibitor of Lyn- BCR/ABL that has been used experimentally for leukemia therapy. From our previous experimental work with bafetinib, it showed an anti-proliferative effect on Ishikawa cell line at concentration of 200nM. This observation was supported by colonogenic assay, the number of colonies formed by Ishikawa cells was 6 folds in the control comparing to bafetinib treated cells. Cells counting also support this finding, Ishikawa treated cells were unable to continue growing after 2 days of the drug addition comparing to the control cells that continued dividing. This underscores the role of bafetinib as anti-neoplastic agent on Ishikawa cells. To understand its mechanism of action, cyclin-dependent kinase inhibitors p16INK4a and p21 WAF1 that have major role in cell cycle arrest were measured. No difference was noticed in p21 levels between the treated and control cells; however, increasing in p16 expression was observed in treated Ishikawa cells. This underlines the role of bafetinib in inhibiting Ishikawa cells through modulating p16 expression. This suggests that bafetinib could be used as a therapy in case of endometrial cancer. But, further work should be conducted to examine the effect of bafetinib on other endometrial cancer cells and on mice before testing its effect on endometrial cancer patients.

Download Full-text

Why Routine Clinical Follow-up for Patients With Early Stage Endometrial Cancer Is Not Always Necessary: A Study on Women in South Wales

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000088 ◽

2014 ◽

Vol 24 (3) ◽

pp. 556-563 ◽

Cited By ~ 7

Author(s):

Lilly Aung ◽

Robert E.J. Howells ◽

Kenneth C.K. Lim ◽

Emma Hudson ◽

Peter W. Jones

Keyword(s):

Endometrial Cancer ◽

Confidence Interval ◽

Endometrial Carcinoma ◽

Early Stage ◽

Progression Free Survival ◽

Disease Recurrence ◽

Hazard Ratio ◽

Free Survival ◽

South Wales

ObjectiveThis study aimed to examine the existing methods of follow-up in women who have undergone treatment of early endometrial carcinoma in South Wales and to assess if they are appropriate.DesignThis study used a retrospective analysis of follow-up data.SettingThis study was performed in the Virtual Gynaecological Oncology Centre, South Wales, United Kingdom.SampleThis study sample is composed of 552 women.MethodsData regarding follow-up were collected retrospectively from patient case notes and computerized data systems. Data were analyzed using the Pearson χ2 test, Cox proportional hazard regression analysis, and Kaplan-Meier curves.Main Outcome MeasuresThis study aimed to determine whether routine follow-up was beneficial in detecting disease recurrence and whether outcome was influenced by routine follow-up.ResultsBetween January 1, 2000, and December 31, 2010, 552 women were treated for early stage endometrial carcinoma. The 5-year survival was 81%, and the 5-year progression-free survival was 77%. Of these 552 women, 81 (15%) developed a disease recurrence; the majority (61/81 [75%]) recurred within 3 years. The median survival was 35 months compared with 47 months in patients who did not develop a recurrence. Of the 81 patients, 73 (90%) were symptomatic and only 5 patients were truly asymptomatic at follow-up. The most important and significant prognostic factor was “recurrent disease” with overall survival (hazard ratio, 2.20; P < 0.001; 95% confidence interval, 1.75–2.65) and progression-free survival (hazard ratio, 2.52; P < 0.001; 95% confidence interval, 2.09–2.95). “Asymptomatic recurrence” was not an independent predictor of outcome.ConclusionsRoutine follow-up for early endometrial cancer is not beneficial for patients because most were symptomatic at the time of detection. It does not significantly improve the outcome. We propose altering the follow-up time regimen and adopting alternative follow-up strategies for women in South Wales.

Download Full-text

Knock Down of LINC00504 Represses Proliferation and Invasion via Regulation of miR-140-5p in Breast Cancer

10.21203/rs.3.rs-39231/v1 ◽

2020 ◽

Author(s):

Tieying Hou ◽

Long Ye ◽

Qingsong Qin ◽

Shulin Wu

Keyword(s):

Breast Cancer ◽

Cell Proliferation ◽

Cell Lines ◽

Breast Cancer Cell ◽

Migration And Invasion ◽

Cancer Cell Proliferation ◽

Breast Cancer Cell Proliferation ◽

Cancer Tissues ◽

Proliferation And Invasion

Abstract Background: Breast cancer is one of the most common cancer in the world. Emerging evidence has demonstrated the critical role of long noncoding RNAs (lncRNAs) in the development of breast cancer. In this study, we aimed to investigate the role of LINC00504 in breast cancer progression. Methods: Quantification real-time PCR was used to analyzed the expression levels of LINC00504 and miR‐140-5p in breast cancer tissues and cell lines. Cell proliferation, migration and invasion were assessed by Cell Counting Kit‐8, transwell assay and Immunofluorescence. Dual-luciferase reporter assay and RNA Immunoprecipitation assay were performed to verify the interaction between LINC00504 and miR‐140-5p. The expression levels of VEGFA, CDH1 and VIM were demonstrated by western blot assays. Result: Here, we found that LINC00504 is up regulated in breast cancer tissues and cell lines. Down regulation of LINC00504 mediated by shRNA suppressed the proliferation, migration, and invasion of breast cancer cells in vitro and in vivo. Furthermore, LINC00504 was found to competitively regulate miR‐140-5p via targeting VEGFA. Inhibition of miR‐140-5p attenuated the knockdown-LINC00504 induced inhibition of breast cancer cell proliferation and invasion.Conclusion: Taken together, our results demonstrated the mechanism of the LINC00504–miR‐140-5p–VEGFA axis in breast cancer cell proliferation and invasion and may lead to new lncRNA-based diagnostics or therapeutics for breast cancer.

Download Full-text

Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer

Medicina ◽

10.3390/medicina55090564 ◽

2019 ◽

Vol 55 (9) ◽

pp. 564 ◽

Cited By ~ 2

Author(s):

Ionut Andrei Paunescu ◽

Razvan Bardan ◽

Anca Marcu ◽

Diana Nitusca ◽

Alis Dema ◽

...

Keyword(s):

Prostate Cancer ◽

Area Under The Curve ◽

Plasma Samples ◽

Tissue Samples ◽

New Class ◽

Non Invasive ◽

Plasma Microrna ◽

Cancer Tissues ◽

Tissue Cancer

Background and Objectives: Over decades, prostate cancer (PCa) has become one of the leading causes of cancer mortality in men. Extensive evidence exists that microRNAs (miRNAs or miRs) are key players in PCa and a new class of non-invasive cancer biomarkers. Materials and Methods: We performed miRNA profiling in plasma and tissues of PCa patients and attempted the validation of candidate individual miRs as biomarkers. Results: The comparison of tissue and plasma profiling results revealed five commonly dysregulated miRs, namely, miR-130a-3p, miR-145-5p, miR-148a-3p, miR-150-5p, and miR-365a-3p, of which only three show concordant changes—miR-130a-3p and miR-150-5p were downregulated and miR-148a-3p was upregulated in both tissue and plasma samples, respectively. MiR-150-5p was validated as significantly downregulated in both plasma and tissue cancer samples, with a fold change of −2.697 (p < 0.001), and −1.693 (p = 0.035), respectively. ROC analysis showed an area under the curve (AUC) of 0.817 (95% CI: 0.680–0.995) for plasma samples and 0.809 (95% CI: 0.616–1.001) for tissue samples. Conclusions: We provide data indicating that miR-150-5p plasma variations in PCa patients are associated with concordant changes in prostate cancer tissues; however, given the heterogeneous nature of previous findings of miR-150-5p expression in PCa cells, additional future studies of a larger sample size are warranted in order to confirm the biomarker potential and role of miRNA-150-5p in PCa biology.

Download Full-text

The Role of Imaging in Advanced Endometrial Carcinoma

European Oncology & Haematology ◽

10.17925/eoh.2009.05.1.68 ◽

2009 ◽

Vol 05 (01) ◽

pp. 68

Author(s):

Helen Addley ◽

Evis Sala ◽

◽

Keyword(s):

Endometrial Carcinoma ◽

Treatment Planning ◽

Endometrial Thickness ◽

Imaging Techniques ◽

Treatment Selection ◽

Histological Diagnosis ◽

Initial Assessment ◽

Oncological Treatment

Imaging in endometrial carcinoma has many roles. It is used in the initial assessment of symptomatic patients for demonstration of abnormal endometrial thickness. Once the histological diagnosis of endometrial carcinoma is confirmed, imaging can accurately stage the tumour, facilitating surgical and oncological treatment planning. This article will review the different imaging techniques available and their roles in staging, treatment selection and follow-up of patients with endometrial carcinoma.

Download Full-text

Hydroethanolic Extracts of the Aristotelia Chilensis (Maqui) Berry Reduces Cellular Viability and Invasiveness in the Endometrial Cancer Cell Line Ishikawa

Integrative Cancer Therapies ◽

10.1177/15347354211007560 ◽

2021 ◽

Vol 20 ◽

pp. 153473542110075

Author(s):

Javier Mena ◽

Estefanía Elgueta ◽

Francisca Espinola-Gonzales ◽

Hugo Cardenas ◽

Pedro A. Orihuela

Keyword(s):

Endometrial Cancer ◽

Cell Viability ◽

Cell Line ◽

Cancer Cell ◽

Cancer Cell Line ◽

Boyden Chamber ◽

Female Population ◽

Endometrial Cancer Cell ◽

Ishikawa Cells ◽

Aristotelia Chilensis

Cancer of the reproductive tract includes diseases with higher prevalence in the female population. This investigation examined whether an anthocyanin-enriched extract of Aristotelia chilensis, commonly known as “maqui,” could affect some hallmarks of endometrial cancer. Cultures of the human endometrial cancer cell line Ishikawa were treated with a hydroethanolic maqui extract at 1, 3, 10, 30, 100, 300, or 1000 µg/mL to determine the effect on cell viability by MTT assay. Then, we used the 50% Effective Concentration (EC50) to evaluate whether the effect of the maqui extract is mediated via an arrest of the cell cycle or induction of apoptosis using flow cytometry or Annexin V-FITC assays, respectively. The effects of sublethal doses of the maqui extract on migration and invasiveness of Ishikawa cells were also evaluated by the wound healing and Boyden Chamber assay, respectively. Our results show that the hydroethanolic maqui extract inhibits the cell viability with an EC50 of 472.3 µg/mL via increased apoptosis, and that reduces the invasive capacity but not migration of Ishikawa cells. These findings suggest that the hydroethanolic maqui extract has antineoplastic properties for endometrial cancer and merits further studies to corroborate its efficiency as anticancer therapy in reproductive organs.

Download Full-text